文献速递银屑病与炎症性皮肤病

口服ME3183(PDE4抑制剂)治疗斑块状银屑病的疗效与安全性

Efficacy and safety of ME3183, an oral phosphodiesterase 4 inhibitor, in patients with plaque psoriasis.
PubMed 文献 · J Eur Acad Dermatol Venereol · 2025-07-25

这项随机、双盲、安慰剂对照研究纳入132例中重度斑块状银屑病患者,按1:1:1:1:1分为ME3183 5 mg每日两次、10 mg每日一次、7.5 mg每日两次、15 mg每日一次及安慰剂组,双盲治疗16周。第16周达到PASI较基线改善≥75%的患者比例在ME3183各组分别为58.3%、32.0%、61.5%和52.0%,安慰剂组为14.8%(除10 mg每日一次组外,其余各组与安慰剂比较p < 0.01)。最常见不良事件为腹泻、恶心和头痛。

要点

  • ME3183 7.5 mg每日两次组PASI 75应答率最高(61.5%),安慰剂组为14.8%。
  • 10 mg每日一次组PASI 75应答率32.0%,与安慰剂比较差异未达统计学显著。
  • 常见不良事件为腹泻、恶心和头痛,需在后续研究中进一步评估安全性。

核心结论

  • ME3183作为安全有效的中重度斑块状银屑病替代治疗选择,值得进一步研究。

研究设计与样本

  • 随机、双盲、安慰剂对照研究,双盲治疗期为16周。
  • 共132例患者按1:1:1:1:1随机分配至ME3183 5 mg每日两次(26例)、10 mg每日一次(26例)、7.5 mg每日两次(26例)、15 mg每日一次(27例)或安慰剂组(27例)。

主要发现

  • 第16周达到PASI较基线改善≥75%的患者比例:5 mg每日两次组58.3%,10 mg每日一次组32.0%,7.5 mg每日两次组61.5%,15 mg每日一次组52.0%,安慰剂组14.8%。
  • 除10 mg每日一次组外,其余ME3183各组与安慰剂比较p < 0.01。
  • ME3183各组最常见不良事件为腹泻(16.0%-38.5%)、恶心(7.7%-30.8%)和头痛(7.7%-42.3%)。

关键数值与推荐

  • 主要终点为第16周PASI较基线改善≥75%的患者比例。
  • ME3183各组PASI 75应答率与安慰剂组比较:除10 mg每日一次组外,均p < 0.01。

临床怎么用

  • ME3183每日两次方案(5 mg或7.5 mg)在16周时显示出优于安慰剂的PASI 75应答,可作为中重度斑块状银屑病口服治疗的候选方案。
  • 用药期间需关注腹泻、恶心和头痛等不良事件。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: There is an unmet need for oral psoriasis medications with improved efficacy and safety. OBJECTIVES: We evaluated the efficacy and safety of oral ME3183, a novel phosphodiesterase 4 inhibitor, in patients with moderate to severe plaque psoriasis. METHODS: This was a randomized, double-blind, placebo-controlled study with a 16-week double-blind treatment period. Patients were randomly assigned (1:1:1:1:1) to oral ME3183 5 mg twice daily (BID), 10 mg once daily (QD), 7.5 mg BID, 15 mg QD or placebo. RESULTS: In total, 132 patients were randomly assigned to ME3183 5 mg BID (26 patients), 10 mg QD (26 patients), 7.5 mg BID (26 patients), 15 mg QD (27 patients) and placebo (27 patients). The proportions of patients achieving ≥75% reduction in baseline Psoriasis Area and Severity Index scores at Week 16 (primary endpoint) were 58.3%, 32.0%, 61.5% and 52.0% in each ME3183 group, respectively, versus 14.8% in the placebo group (all p < 0.01 vs. placebo, except for the 10 mg QD group). The most common adverse events across the ME3183 groups were diarrhoea (16.0%-38.5%), nausea (7.7%-30.8%) and headache (7.7%-42.3%). CONCLUSIONS: ME3183 should be further investigated as a safe and effective treatment alternative for moderate to severe plaque psoriasis.

来源:J Eur Acad Dermatol Venereol,查看原文。版权归原作者所有。

引用

  1. Papp KA, Armstrong AW, Koresawa T, et al. Efficacy and safety of ME3183, an oral phosphodiesterase 4 inhibitor, in patients with plaque psoriasis. J Eur Acad Dermatol Venereol. 2025. PMID: 40715001. doi:10.1111/jdv.20863

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。